Alexandre Iannello

Alexandre Iannello brings a deep, wide-ranging experience in immunology and drug development as a lead of the Discovery Pharmacology team at Sonoma Biotherapeutics, where he is responsible for characterizing and validating Sonoma’s therapies and technologies. Over the last decade, he was most recently a part of Actym Therapeutics, Abbvie’s Stemcentrx, and Rigel Pharmaceuticals. Iannello held post-doctoral positions in Dr. David Raulet’s laboratory at the University of California, Berkeley, where he worked on tumor immunology, NK cell biology, and mechanisms of tumor suppression.

Dr. Iannello earned a Ph.D. in virology and immunology from the University of Montreal and a DESS in bioinformatics from the University of Quebec in Montreal (UQAM.) He holds an M.A. in microbiology from Pasteur Institute in Paris, France, and BSc from Joseph Fourier University.